Health Canada approves TRESIBA® for children with Type 1 diabetes

Novo Nordisk Canada Inc. announces TRESIBA® (insulin degludec injection) has received an expanded Health Canada approval for the treatment of pediatric patients (>2 years of age) with Type 1 diabetes mellitus. TRESIBA® is an ultra-long-acting basal in https://www.newswire.ca/news-releases/health-canada-approves-tresiba-for-children-with-type-1-diabetes-694779711.html